These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31651452)

  • 1. Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors.
    He L; Liu Y; Han H; Liu Z; Huang S; Cao W; Liu B; Qin Z; Guo S; Zhang Z; Lin M; Jiang X; Lin C; Li Y; Yao K; Dong P; Zhou F
    Am J Clin Oncol; 2020 Jan; 43(1):58-63. PubMed ID: 31651452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.
    Cheung P; Patel S; North SA; Sahgal A; Chu W; Soliman H; Ahmad B; Winquist E; Niazi T; Patenaude F; Lim G; Heng DYC; Dubey A; Czaykowski P; Wong RKS; Swaminath A; Morgan SC; Mangat R; Keshavarzi S; Bjarnason GA
    Eur Urol; 2021 Dec; 80(6):693-700. PubMed ID: 34399998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
    Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27.
    Stellato M; Buti S; Maruzzo M; Bassanelli M; Bersanelli M; Napoli MD; Dionese M; Fanelli M; Filippi R; Fotia G; Galli L; Grillone F; Maffezzoli M; Maiorano BA; Nasso C; Rebuzzi SE; Lalli L; Roviello G; Sorarù M; Vincenzi B; Procopio G; Verzoni E
    Clin Genitourin Cancer; 2024 Jun; 22(3):102078. PubMed ID: 38631104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
    Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study.
    Buti S; Bersanelli M; Viansone A; Leonetti A; Masini C; Ratta R; Procopio G; Maines F; Iacovelli R; Ciccarese C; Vitale MG; De Giorgi U; Mucciarini C; Maruzzo M; Prati G; Lattanzi E; Ciammella P; Bruni A; Andreani S; D'Abbiero N
    Cancer Treat Res Commun; 2020; 22():100161. PubMed ID: 31677494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
    Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
    Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World.
    Gebbia V; Girlando A; DI Grazia A; Fazio I; Borsellino N; Piazza D; Serretta V; Pergolizzi S; Pontoriero A; Firenze A; Valerio MR
    Anticancer Res; 2020 Dec; 40(12):7037-7043. PubMed ID: 33288600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study.
    Onal C; Oymak E; Guler OC; Tilki B; Yavas G; Hurmuz P; Yavas C; Ozyigit G
    Strahlenther Onkol; 2023 May; 199(5):456-464. PubMed ID: 36450836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study.
    Majidova N; Seyyar M; Bayraktar DI; Dinç G; İsgandarov E; Huseynov J; Yaşar A; Çelebi A; Sever N; Kocaaslan E; Erel P; Ağyol Y; Güren AK; Arıkan R; Işık S; Ercelep Ö; Demirağ G; Kefeli U; Köstek O; Bayoğlu İV; Sarı M
    Biomol Biomed; 2024 Oct; 24(6):1776-1784. PubMed ID: 38920621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma.
    Liu Y; Zhang Z; Liu R; Wei W; Zhang Z; Mai L; Guo S; Han H; Zhou F; He L; Dong P
    Radiat Oncol; 2021 Nov; 16(1):211. PubMed ID: 34727963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma.
    Verma J; Jonasch E; Allen PK; Weinberg JS; Tannir N; Chang EL; Mahajan A
    Am J Clin Oncol; 2013 Dec; 36(6):620-4. PubMed ID: 22892430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
    Santoni M; Buti S; Myint ZW; Maruzzo M; Iacovelli R; Pichler M; Kopecky J; Kucharz J; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Kopp RM; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Massari F; Seront E; Calabrò F; Pinto A; Berardi R; Zgura A; Mammone G; Ansari J; Atzori F; Chiari R; Bamias A; Caffo O; Procopio G; Sunela K; Bassanelli M; Ortega C; Grillone F; Landmesser J; Milella M; Messina C; Küronya Z; Mosca A; Bhuva D; Santini D; Vau N; Morelli F; Incorvaia L; Rebuzzi SE; Roviello G; Soares A; Bisonni R; Bimbatti D; Zabalza IO; Rizzo A; Mollica V; Sorgentoni G; Monteiro FSM; Battelli N; Bracarda S; Porta C
    Eur Urol Oncol; 2024 Feb; 7(1):102-111. PubMed ID: 37481365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
    Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
    Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H; Imai S; Harada K; Fujisawa M
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.
    Albiges L; Oudard S; Negrier S; Caty A; Gravis G; Joly F; Duclos B; Geoffrois L; Rolland F; Guillot A; Laguerre B; Legouffe E; Kohser F; Dietrich PY; Theodore CA; Escudier B
    J Clin Oncol; 2012 Feb; 30(5):482-7. PubMed ID: 22231040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
    Park I; Lee JL; Ahn JH; Lee DH; Lee KH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
    Cancer Chemother Pharmacol; 2015 May; 75(5):1025-35. PubMed ID: 25776906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients.
    Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
    Cancer Immunol Immunother; 2018 Jan; 67(1):79-87. PubMed ID: 28918459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.